Edwards' PROGRESS Trial: TAVR Lowers Death or Heart Failure Risk by a Third
The PROGRESS trial found TAVR cut the combined risk of death or heart failure events by 33% over two years versus clinical surveillance.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Edwards Lifesciences (EW) reported Phase 3 results from its PROGRESS trial. Transcatheter aortic valve replacement proved superior to clinical surveillance in patients with moderate aortic stenosis who showed features linked to a higher risk of the disease worsening.
Over two years, TAVR reduced the combined endpoint of death or heart failure events by 33%, with rates of 16.7% versus 23.9%. Heart failure hospitalizations more than halved, falling to 7.4% from 14.9%. No deaths and no disabling strokes were reported within 30 days of the procedure.
The study enrolled 744 patients at 74 sites in six countries and was published in the New England Journal of Medicine. The information is based on TradingView reporting.
why it matters
For Edwards, this is a meaningful signal. If doctors and regulators move toward earlier intervention, the pool of potential patients for its SAPIEN 3 valves could widen. The company plans to report its third-quarter 2026 results on November 4, after the market closes, and investors will likely watch closely for updates on the trial.
market impact
Edwards Lifesciences shares: positive trial data widens the patient pool for the company's valves
- Edwards Lifesciences shares pressure up — positive trial data widens the potential market for SAPIEN 3 valves
tags
instruments
sources
- Edwards' TAVR Cuts Risk Of Death Or Heart Failure Events In Moderate Aortic Stenosis Trial — TradingView, 3 November 2026 at 04:41 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗